Skip to main content
Top
Published in: Current Rheumatology Reports 1/2010

01-02-2010

Molecular Pathogenesis of Skin Fibrosis: Insight from Animal Models

Authors: Gideon P. Smith, Edwin S. L. Chan

Published in: Current Rheumatology Reports | Issue 1/2010

Login to get access

Abstract

Skin fibrosis occurs in a variety of human diseases, most notably systemic sclerosis (SSc). The end stage of scleroderma in human skin consists of excess collagen deposition in the dermis with loss of adnexal structures and associated adipose tissue. The initiating factors for this process and the early stages are believed to occur through vascular injury and immune dysfunction with a dysregulated inflammatory response. However, because of the insidious onset of the disease, this stage is rarely observed in humans and remains poorly understood. Animal models have provided a means to examine these early stages and to isolate and understand the effect of perturbations in signaling pathways, chemokines, and cytokines. This article summarizes recent progress in the understanding of the molecular pathogenesis of skin fibrosis in SSc from different animal models, both its initiation and its maintenance phases.
Literature
1.
go back to reference Siracusa LD, McGrath R, Ma Q, et al.: A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996, 6:300–313.CrossRefPubMed Siracusa LD, McGrath R, Ma Q, et al.: A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996, 6:300–313.CrossRefPubMed
2.
go back to reference •• Bayle J, Fitch J, Jacobsen K, et al.: Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol 2008, 128:871–881. This paper showed via microarray studies, as well as RNase protection and northern blot, that Wnt signaling was upregulated via SFRP4 in Tsk mice and that SFRP4 was also upregulated in human SSc lesional skin, providing a strong case for involvement of this pathway in human SSc pathogenesis. •• Bayle J, Fitch J, Jacobsen K, et al.: Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol 2008, 128:871–881. This paper showed via microarray studies, as well as RNase protection and northern blot, that Wnt signaling was upregulated via SFRP4 in Tsk mice and that SFRP4 was also upregulated in human SSc lesional skin, providing a strong case for involvement of this pathway in human SSc pathogenesis.
3.
go back to reference Jimenez SA, Williams CJ, Myers JC, Bashey RI: Increased collagen biosynthesis and increased expression of type I and type III procollagen genes in tight skin (TSK) mouse fibroblasts. J Biol Chem 1986, 261:657–662.PubMed Jimenez SA, Williams CJ, Myers JC, Bashey RI: Increased collagen biosynthesis and increased expression of type I and type III procollagen genes in tight skin (TSK) mouse fibroblasts. J Biol Chem 1986, 261:657–662.PubMed
4.
go back to reference Ong CJ, Ip S, Teh SJ, et al.: A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999, 196:60–68.CrossRefPubMed Ong CJ, Ip S, Teh SJ, et al.: A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999, 196:60–68.CrossRefPubMed
5.
go back to reference McGaha T, Saito S, Phelps RG, et al.: Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol 2001, 116:136–143.CrossRefPubMed McGaha T, Saito S, Phelps RG, et al.: Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol 2001, 116:136–143.CrossRefPubMed
6.
go back to reference Saito E, Fujimoto M, Hasegawa M, et al.: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453–1462.PubMed Saito E, Fujimoto M, Hasegawa M, et al.: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002, 109:1453–1462.PubMed
7.
go back to reference Gentiletti J, McCloskey LJ, Artlett CM, et al.: Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma. J Immunol 2005, 175:2418–2426.PubMed Gentiletti J, McCloskey LJ, Artlett CM, et al.: Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma. J Immunol 2005, 175:2418–2426.PubMed
8.
go back to reference Christner PJ, Hitraya EG, Peters J, et al.: Transcriptional activation of the alpha1(I) procollagen gene and up-regulation of alpha1(I) and alpha1(III) procollagen messenger RNA in dermal fibroblasts from tight skin 2 mice. Arthritis Rheum 1998, 41:2132–2142.CrossRefPubMed Christner PJ, Hitraya EG, Peters J, et al.: Transcriptional activation of the alpha1(I) procollagen gene and up-regulation of alpha1(I) and alpha1(III) procollagen messenger RNA in dermal fibroblasts from tight skin 2 mice. Arthritis Rheum 1998, 41:2132–2142.CrossRefPubMed
9.
go back to reference Barisic-Dujmovic T, Boban I, Clark SH: Regulation of collagen gene expression in the Tsk2 mouse. J Cell Physiol 2008, 215:464–471.CrossRefPubMed Barisic-Dujmovic T, Boban I, Clark SH: Regulation of collagen gene expression in the Tsk2 mouse. J Cell Physiol 2008, 215:464–471.CrossRefPubMed
10.
go back to reference Saito S, Nishimura H, Phelps RG, et al.: Induction of skin fibrosis in mice expressing a mutated fibrillin-1 gene. Mol Med 2000, 6:825–836.PubMed Saito S, Nishimura H, Phelps RG, et al.: Induction of skin fibrosis in mice expressing a mutated fibrillin-1 gene. Mol Med 2000, 6:825–836.PubMed
11.
go back to reference •• Sonnylal S, Denton CP, Zheng B, et al.: Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007, 56:334–344. This paper reported on a novel transgenic mouse model in which the TGF-β signaling pathway could be activated in fibroblasts postnatally. This model would provide an excellent model for testing of TGF-β-based therapies. This model is also important as it demonstrates the potential of transgenic models. The same approach but with different target genes may in the future be used to test other very specific hypotheses. •• Sonnylal S, Denton CP, Zheng B, et al.: Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 2007, 56:334–344. This paper reported on a novel transgenic mouse model in which the TGF-β signaling pathway could be activated in fibroblasts postnatally. This model would provide an excellent model for testing of TGF-β-based therapies. This model is also important as it demonstrates the potential of transgenic models. The same approach but with different target genes may in the future be used to test other very specific hypotheses.
12.
go back to reference Denton CP, Zheng B, Evans LA, et al.: Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. J Biol Chem 2003, 278:25109–25119.CrossRefPubMed Denton CP, Zheng B, Evans LA, et al.: Fibroblast-specific expression of a kinase-deficient type II transforming growth factor beta (TGFbeta) receptor leads to paradoxical activation of TGFbeta signaling pathways with fibrosis in transgenic mice. J Biol Chem 2003, 278:25109–25119.CrossRefPubMed
13.
go back to reference Samuel CS, Zhao C, Yang Q, et al.: The relaxin gene knockout mouse: a model of progressive scleroderma. J Invest Dermatol 2005, 125:692–699.CrossRefPubMed Samuel CS, Zhao C, Yang Q, et al.: The relaxin gene knockout mouse: a model of progressive scleroderma. J Invest Dermatol 2005, 125:692–699.CrossRefPubMed
14.
go back to reference Yamamoto T, Takagawa S, Katayama I, Nishioka K: Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999, 92:6–13.CrossRefPubMed Yamamoto T, Takagawa S, Katayama I, Nishioka K: Anti-sclerotic effect of transforming growth factor-beta antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999, 92:6–13.CrossRefPubMed
15.
go back to reference Yamamoto T, Kuroda M, Nishioka K: Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000, 292:535–541.CrossRefPubMed Yamamoto T, Kuroda M, Nishioka K: Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000, 292:535–541.CrossRefPubMed
16.
go back to reference Takagawa S, Lakos G, Mori Y, et al.: Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003, 121:41–50.CrossRefPubMed Takagawa S, Lakos G, Mori Y, et al.: Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol 2003, 121:41–50.CrossRefPubMed
17.
go back to reference Bhattacharyya S, Ghosh AK, Pannu J, et al.: Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum 2005, 52:1248–1258.CrossRefPubMed Bhattacharyya S, Ghosh AK, Pannu J, et al.: Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum 2005, 52:1248–1258.CrossRefPubMed
18.
go back to reference • Mori Y, Hinchcliff M, Wu M, et al.: Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness. Exp Cell Res 2008, 314:1094–1104. Although CCN2 has been speculated to be important in the pathogenesis of fibrosis, this paper indicated that it was less important in Smad-dependent stimulation of collagen. • Mori Y, Hinchcliff M, Wu M, et al.: Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness. Exp Cell Res 2008, 314:1094–1104. Although CCN2 has been speculated to be important in the pathogenesis of fibrosis, this paper indicated that it was less important in Smad-dependent stimulation of collagen.
19.
go back to reference Lakos G, Takagawa S, Chen SJ, et al.: Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004, 165:203–217.PubMed Lakos G, Takagawa S, Chen SJ, et al.: Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004, 165:203–217.PubMed
20.
go back to reference Chen SJ, Ning H, Ishida W, et al.: The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006, 281:21183–21197.CrossRefPubMed Chen SJ, Ning H, Ishida W, et al.: The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006, 281:21183–21197.CrossRefPubMed
21.
go back to reference Ghosh AK, Bhattacharyya S, Lakos G, et al.: Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004, 50:1305–1318.CrossRefPubMed Ghosh AK, Bhattacharyya S, Lakos G, et al.: Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004, 50:1305–1318.CrossRefPubMed
22.
go back to reference • Wu M, Melichian DS, Chang E, et al.: Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009, 174:519–533. This article demonstrated reduced fibrosis in a scleroderma model using a PPAR-γ blocker and thus a further potential therapeutic target. • Wu M, Melichian DS, Chang E, et al.: Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009, 174:519–533. This article demonstrated reduced fibrosis in a scleroderma model using a PPAR-γ blocker and thus a further potential therapeutic target.
23.
go back to reference Jinnin M, Ihn H, Mimura Y, et al.: Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts. J Invest Dermatol 2005, 124:324–330.CrossRefPubMed Jinnin M, Ihn H, Mimura Y, et al.: Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts. J Invest Dermatol 2005, 124:324–330.CrossRefPubMed
24.
go back to reference Wu MH, Yokozeki H, Takagawa S, et al.: Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Ther 2004, 11:170–180.CrossRefPubMed Wu MH, Yokozeki H, Takagawa S, et al.: Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Ther 2004, 11:170–180.CrossRefPubMed
25.
go back to reference Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994, 76:5–13.PubMed Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994, 76:5–13.PubMed
26.
go back to reference Montesinos MC, Desai A, Chen JF, et al.: Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol 2002, 160:2009–2018.PubMed Montesinos MC, Desai A, Chen JF, et al.: Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol 2002, 160:2009–2018.PubMed
27.
go back to reference Chan ES, Fernandez P, Merchant AA, et al.: Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum 2006, 54:2632–2642.CrossRefPubMed Chan ES, Fernandez P, Merchant AA, et al.: Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum 2006, 54:2632–2642.CrossRefPubMed
28.
go back to reference Fernández P, Trzaska S, Wilder T, et al.: Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine. Am J Pathol 2008, 172:1675–1682.CrossRefPubMed Fernández P, Trzaska S, Wilder T, et al.: Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine. Am J Pathol 2008, 172:1675–1682.CrossRefPubMed
29.
go back to reference Ferreira AM, Takagawa S, Fresco R, et al.: Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 2006, 126:1900–1908.CrossRefPubMed Ferreira AM, Takagawa S, Fresco R, et al.: Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 2006, 126:1900–1908.CrossRefPubMed
30.
go back to reference • Liu S, Kapoor M, Denton CP, et al.: Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum 2009, 60:2817–2821. This article showed via a β1 integrin-deficient murine model that β1 integrin expression by fibroblasts is required for fibrogenesis and that its inhibition may therefore provide a further therapeutic target. • Liu S, Kapoor M, Denton CP, et al.: Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum 2009, 60:2817–2821. This article showed via a β1 integrin-deficient murine model that β1 integrin expression by fibroblasts is required for fibrogenesis and that its inhibition may therefore provide a further therapeutic target.
31.
go back to reference Lakos G, Melichian D, Wu M, Varga J: Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 2006, 73:224–237.CrossRefPubMed Lakos G, Melichian D, Wu M, Varga J: Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 2006, 73:224–237.CrossRefPubMed
32.
go back to reference Aliprantis AO, Wang J, Fathman JW, et al.: Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A 2007, 104:2827–2930.CrossRefPubMed Aliprantis AO, Wang J, Fathman JW, et al.: Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci U S A 2007, 104:2827–2930.CrossRefPubMed
33.
go back to reference Ishikawa H, Takeda K, Okamoto A, et al.: Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells. J Invest Dermatol 2009, 129:1688–1695.CrossRefPubMed Ishikawa H, Takeda K, Okamoto A, et al.: Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells. J Invest Dermatol 2009, 129:1688–1695.CrossRefPubMed
34.
go back to reference Czuwara-Ladykowska J, Shirasaki F, Jackers P, et al.: Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001, 276:20839–20848.CrossRefPubMed Czuwara-Ladykowska J, Shirasaki F, Jackers P, et al.: Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001, 276:20839–20848.CrossRefPubMed
35.
go back to reference Kubo M, Czuwara-Ladykowska J, Moussa O, et al.: Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003, 163:571–581.PubMed Kubo M, Czuwara-Ladykowska J, Moussa O, et al.: Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003, 163:571–581.PubMed
36.
go back to reference Nakerakanti SS, Kapanadze B, Yamasaki M, et al.: Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006, 281:25259–25269.CrossRefPubMed Nakerakanti SS, Kapanadze B, Yamasaki M, et al.: Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006, 281:25259–25269.CrossRefPubMed
37.
go back to reference •• Asano Y, Czuwara J, Trojanowska M: Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007, 282:34672–34683. This article provides evidence of the posttranslational mechanisms regulating Fli1 function and its relation to TGF-α. •• Asano Y, Czuwara J, Trojanowska M: Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007, 282:34672–34683. This article provides evidence of the posttranslational mechanisms regulating Fli1 function and its relation to TGF-α.
38.
go back to reference Zhang Y, McCormick LL, Desai SR, et al.: Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002, 168:3088–3098.PubMed Zhang Y, McCormick LL, Desai SR, et al.: Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 2002, 168:3088–3098.PubMed
39.
go back to reference • Askew D, Zhou L, Wu C, et al.: Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007, 127:1905–1914. This article provides evidence supporting an important role for TNF-α in fibrogenesis. • Askew D, Zhou L, Wu C, et al.: Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 2007, 127:1905–1914. This article provides evidence supporting an important role for TNF-α in fibrogenesis.
40.
go back to reference Ruzek MC, Jha S, Ledbetter S, et al.: A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 2004, 50:1319–1331.CrossRefPubMed Ruzek MC, Jha S, Ledbetter S, et al.: A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 2004, 50:1319–1331.CrossRefPubMed
41.
go back to reference Le Hir M, Martin M, Haas C: A syndrome resembling human systemic sclerosis (scleroderma) in MRL/lpr mice lacking interferon-gamma (IFN-gamma) receptor (MRL/lprgammaR-/-). Clin Exp Immunol 1999, 115:281–287.CrossRefPubMed Le Hir M, Martin M, Haas C: A syndrome resembling human systemic sclerosis (scleroderma) in MRL/lpr mice lacking interferon-gamma (IFN-gamma) receptor (MRL/lprgammaR-/-). Clin Exp Immunol 1999, 115:281–287.CrossRefPubMed
42.
go back to reference Sgonc R, Gruschwitz MS, Dietrich H, et al.: Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996, 98:785–792.CrossRefPubMed Sgonc R, Gruschwitz MS, Dietrich H, et al.: Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996, 98:785–792.CrossRefPubMed
43.
go back to reference Carvalho D, Savage CO, Black CM, Pearson JD: IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 1996, 97:111–119.CrossRefPubMed Carvalho D, Savage CO, Black CM, Pearson JD: IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 1996, 97:111–119.CrossRefPubMed
44.
go back to reference Gruschwitz MS, Moormann S, Krömer G, et al.: Phenotypic analysis of skin infiltrates in comparison with peripheral blood lymphocytes, spleen cells and thymocytes in early avian scleroderma. J Autoimmun 1991, 4:577–593.CrossRefPubMed Gruschwitz MS, Moormann S, Krömer G, et al.: Phenotypic analysis of skin infiltrates in comparison with peripheral blood lymphocytes, spleen cells and thymocytes in early avian scleroderma. J Autoimmun 1991, 4:577–593.CrossRefPubMed
45.
go back to reference Sgonc R: The vascular perspective of systemic sclerosis: of chickens, mice and men. Int Arch Allergy Immunol 1999, 120:169–176.CrossRefPubMed Sgonc R: The vascular perspective of systemic sclerosis: of chickens, mice and men. Int Arch Allergy Immunol 1999, 120:169–176.CrossRefPubMed
Metadata
Title
Molecular Pathogenesis of Skin Fibrosis: Insight from Animal Models
Authors
Gideon P. Smith
Edwin S. L. Chan
Publication date
01-02-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 1/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-009-0080-7

Other articles of this Issue 1/2010

Current Rheumatology Reports 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.